Peripheral neuropathy of the lower limb of type2 diabetes.
Conditions
Interventions
Intervention 1: Intervention group: Tecar on + Laser off. Intervention 2: Intervention group: Tecar on + Laser on. Intervention 3: Intervention group: Laser on + Tecar off.
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
50 Years to No maximum
Inclusion criteria
Inclusion criteria: Age over 50 years Diagnosis of type2 diabetes by endocrinologist and neurologist Minimum pain score of 4 based on visual analog scale(VAS) Body mass index < 30 Nerve conduction velocity(Ncv) < 40 tibial motor nerve Controlled blood sugar for last three months(Glycosylated hemoglobin Hba1c < 8.5)
Exclusion criteria
Exclusion criteria: The presence of symptoms of non diabetic neuropathy Systemic peripheral vascular involvement Pregnancy Patients with malignant tumors Chronic coronary artery,lung and kidney diseases Patients with pacemakers or mechanical insulin pumps Patient with knee joint teplacement and the presence of metal plaque in the lower limb Patients addicted to drugs, cigarettes and alcohol
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pain. Timepoint: Before, after10 session and 3month after intervention. Method of measurement: Visual analogue scale (numerical)(VAS).;Nerve conduction velocity, tibial motor nerve. Timepoint: Before, after10 session and 3month after intervention. Method of measurement: Electromyography device.;The feeling of tactile soles of the foot. Timepoint: Before, after10 sessions and 3month after intervention. Method of measurement: By Sims Weinstein 10g monofilament ten points on the soles of the feet will be evaluated.;Mishigan questionnaire. Timepoint: Before, after10 sessions and 3month after intervention. Method of measurement: The questionnaire has two parts, one part evaluates and records by evaluator and the other part fills by patient.;Ankle brachial index, it is the ratio of ankle systolic blood pressure to arm systolic blood pressure. Timepoint: Before, after10 sessions and 3month after intervention. Method of measurement: By digital sphygmomanometer.;Sensory Sural nerve amplitude. Timepoint: Before, after10 sessions and 3month after intervention. Method of measurement: Electromyography device. | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of life. Timepoint: Befor intervention and after three months10 session intervention. Method of measurement: Summary questionnaire of 26 questions of the World Health Organization. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMitra Javan Amoli
Shahid Beheshti University of Medical Sciences
Outcome results
None listed